These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25132656)

  • 1. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
    Wentzensen N; Fetterman B; Tokugawa D; Schiffman M; Castle PE; Wood SN; Stiemerling E; Poitras N; Lorey T; Kinney W
    Cancer Cytopathol; 2014 Dec; 122(12):914-20. PubMed ID: 25132656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
    Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
    Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.
    Waldstrøm M; Christensen RK; Ørnskov D
    Cancer Cytopathol; 2013 Mar; 121(3):136-45. PubMed ID: 22987560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
    Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
    J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.
    Solares C; Velasco J; Álvarez-Ruiz E; González-Fernández L; Encinas AI; Astudillo A; Schneider J
    Anticancer Res; 2015 Nov; 35(11):6291-5. PubMed ID: 26504065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
    Petry KU; Schmidt D; Scherbring S; Luyten A; Reinecke-Lüthge A; Bergeron C; Kommoss F; Löning T; Ordi J; Regauer S; Ridder R
    Gynecol Oncol; 2011 Jun; 121(3):505-9. PubMed ID: 21420158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.
    Bergeron C; Ikenberg H; Sideri M; Denton K; Bogers J; Schmidt D; Alameda F; Keller T; Rehm S; Ridder R;
    Cancer Cytopathol; 2015 Jun; 123(6):373-81. PubMed ID: 25891096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
    Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
    Liu W; Gong J; Xu H; Zhang D; Xia N; Li H; Song K; Lv T; Chen Y; Diao Y; Jao J; Dai S; Zhao P; Yao Q
    Diagn Cytopathol; 2020 Jul; 48(7):635-644. PubMed ID: 32275355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
    Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
    Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of p16/Ki-67 adequacy and positivity in HPV-positive women from a screening population.
    Benevolo M; Mancuso P; Allia E; Gustinucci D; Bulletti S; Cesarini E; Carozzi FM; Confortini M; Bisanzi S; Rubino T; Rollo F; Marchi N; Farruggio A; Pusiol T; Venturelli F; Giorgi Rossi P;
    Cancer Cytopathol; 2021 May; 129(5):383-393. PubMed ID: 33142029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
    Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
    Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
    Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual immunostaining of cervical cytology specimens with atypical squamous cells for p16/Ki-67 does not exclude the existence of a high-grade squamous intraepithelial lesion.
    Koo YJ; Hahn HS; Lee IH; Lim KT; Lee KH; Kim HS; Kim TJ; Chun YK; Kim HS; Hong SR
    Virchows Arch; 2013 Nov; 463(5):689-96. PubMed ID: 24081504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interlaboratory concordance of p16/Ki-67 dual-staining interpretation in HPV-positive women in a screening population.
    Benevolo M; Mancuso P; Allia E; Gustinucci D; Bulletti S; Cesarini E; Carozzi FM; Confortini M; Bisanzi S; Carlinfante G; Rubino T; Rollo F; Marchi N; Farruggio A; Pusiol T; Venturelli F; Giorgi Rossi P;
    Cancer Cytopathol; 2020 May; 128(5):323-332. PubMed ID: 32168431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
    Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
    Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study.
    Schmidt D; Bergeron C; Denton KJ; Ridder R;
    Cancer Cytopathol; 2011 Jun; 119(3):158-66. PubMed ID: 21442767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
    Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
    JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
    Polman NJ; Uijterwaal MH; Witte BI; Berkhof J; van Kemenade FJ; Spruijt JW; van Baal WM; Graziosi PG; van Dijken DK; Verheijen RH; Helmerhorst TJ; Steenbergen RD; Heideman DA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2017 Jan; 140(2):423-430. PubMed ID: 27677098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.